Form 8-K - Current report:
SEC Accession No. 0001104659-24-004966
Filing Date
2024-01-19
Accepted
2024-01-19 06:05:44
Documents
12
Period of Report
2024-01-19
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm243583d3_8k.htm   iXBRL 8-K 36538
  Complete submission text file 0001104659-24-004966.txt   212321

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ewtx-20240119.xsd EX-101.SCH 3021
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ewtx-20240119_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ewtx-20240119_pre.xml EX-101.PRE 22363
6 EXTRACTED XBRL INSTANCE DOCUMENT tm243583d3_8k_htm.xml XML 3311
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40236 | Film No.: 24543649
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)